Search company, investor...

CSF Therapeutics

Founded Year



Unattributed VC | Alive

Total Raised


Last Raised

$4M | 17 yrs ago

About CSF Therapeutics

CSF Therapeutics is developing a cerebral blood flow device to prevent neurological debilitation and death, affecting more than 10 million individuals in the US alone, and includes indications such as stroke and Alzheimer's disease. Based on the research at The Cleveland Clinic, CSF Therapeutics' device is designed to increase cerebral blood flow indefinitely without affecting vascular or systemic function.

Headquarters Location

10265 Carnegie Avenue

Cleveland, Ohio, 44106,

United States


Missing: CSF Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CSF Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing CSF Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CSF Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CSF Therapeutics Patents

CSF Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Neurotrauma, Ventricular System, Neurology, Cardiovascular physiology, Fluid dynamics


Application Date


Grant Date



Related Topics

Neurotrauma, Ventricular System, Neurology, Cardiovascular physiology, Fluid dynamics



CSF Therapeutics Frequently Asked Questions (FAQ)

  • When was CSF Therapeutics founded?

    CSF Therapeutics was founded in 2006.

  • Where is CSF Therapeutics's headquarters?

    CSF Therapeutics's headquarters is located at 10265 Carnegie Avenue, Cleveland.

  • What is CSF Therapeutics's latest funding round?

    CSF Therapeutics's latest funding round is Unattributed VC.

  • How much did CSF Therapeutics raise?

    CSF Therapeutics raised a total of $4M.

  • Who are the investors of CSF Therapeutics?

    Investors of CSF Therapeutics include Norwich Ventures.

  • Who are CSF Therapeutics's competitors?

    Competitors of CSF Therapeutics include Juventas Therapeutics, Proteon Therapeutics, Pervasis Therapeutics, Synosia Therapeutics, Chimeros and 14 more.

Compare CSF Therapeutics to Competitors

EndGenitor Technologies

EndGenitor scientists are also engaged in exciting research to novel methods for stimulating and promoting blood vessel formation and growth.

ImaRx Therapeutics

We are a biopharmaceutical company developing and commercializing therapies for vascular disorders. Our research and development efforts are focused on therapies for stroke and other vascular disorders, using our proprietary microbubble technology to treat vascular occlusions, or blood vessel blockages, as well as the resulting ischemia, which is tissue damage caused by a reduced supply of oxygen. In addition to the brain and the lungs, blood clots can block blood flow and cause damage to other tissues in the body such as the heart, in case of coronary arterial disease, and the legs and other extremities, in case of peripheral vascular disease. We believe our development and research stage products may address significant unmet medical needs not only for stroke but also for clot-induced damage in tissues other than the brain.


Angiogenix, Inc. is an early-stage biotechnology company developing products for peripheral and cardiac ischemia. The Company's ACCLAIM(tm product candidates are proprietary nitrates focused on replacing a significant share of existing generic nitrate products with worldwide sales of about $3 billion. The Company's Vasotrophin(r product candidate is a novel angiogenic growth factor that stimulates both angiogenesis and arteriogenesis to produce robust new blood vessels. Vasotrophin can be injected directly into peripheral tissue and used with proven catheter technologies for cardiovascular applications. Angiogenix is located in Burlingame, California.

Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

CoImmune Logo

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.


Nanotope is a regenerative medicine company that leverages a core set of technologies to address multiple therapeutic markets. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope's lead products target neuron regeneration for prevention or reversal of paralysis associated with spinal cord injury and angiogenesis for wound healing and the treatment of peripheral artery disease.n

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.